Insights Into Lung Cancer
Perspectives on the treatment practices and recent updates in EGFR-positive non-small cell lung cancer (NSCLC), including first-line treatment strategies, postprogression and second-line-and-beyond sequencing approaches, and emerging regimens and clinical data.
West – May 16, 2026
Faculty Chair
Edward Kim, MD, MBA, FACP, FASCO
City of Hope, Irvine, CA, USA
Insights Obtained From
- California, Nevada
REPORT SNAPSHOT
- First-line therapy for EGFR-positive NSCLC
- Post-progression and second-line-and-beyond sequencing strategies for EGFR-positive NSCLC
- Emerging regimens, clinical data, and real-world adoption considerations
- Detailed insights and attendee takeaways
- ARS data
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collection was accomplished through the use of audience response system questioning and moderated discussion
- The group of experts comprised 10–15 community oncologists representative of each region
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.